Literature DB >> 27090515

Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences.

Nina Chanishvili1.   

Abstract

Bacteriophage (from 'bacteria' and Greek φαγεῖν phagein "to devour" or bacterial eaters) are bacterial viruses that infect and kill bacteria. Bacteriophages (shortly "phages") are among the most common and diverse entities in the biosphere. The estimated number of phages on earth is about 1032. Bacteriophages are often isolated from environmental sources, such as water samples, etc. Felix d'Herelle, one of the discoverers of bacteriophages, was the one who suggested them for therapy of human and animal bacterial infections. This idea was very popular in the world until the advent of antibiotics commercial after which production of therapeutic phages ceased in most of the Western countries, but not in the former Soviet Union. The application of antibiotics in the clinical practice, besides the well-known side effects, entails, in addition, the appearance of the forms of bacteria, resistant to newly synthesized preparations. It was concluded that a European and global strategy to address this gap is urgently needed. Now, faced with the alarming growth of a variety of antibiotic resistant bacterial infections, Western researchers and governments are giving phages a serious look. The phages nowadays are seen as a possible therapy against multi-drug-resistant strains of many bacteria. The therapeutic action of bacteriophages significantly differs from antibiotics, which makes them still active against multi-drug-resistant bacteria. Bacteriophages have a number of other advantages in comparison with antibiotics. First of all, they are efficient against multi-drug-resistant bacteria. The aim of this review was to provide an overview of the past and current experiences in the field of phage therapy in the countries where it has been traditionally applied in the clinical practice. Although the style and quality of old Soviet scientific publications dedicated to phage therapy are not challenging the international standards, there is still valuable information which may not be neglected by modern researchers. This information is especially important as it remained unavailable for the Western scientists before because of the language barriers until now. The goal of this article is to encourage further research on this topic, and facilitate rapid decisions on the development of appropriate regulations, which would ultimately permit the use of phages as therapeutic or preventative medicines in daily clinical practice in the Western countries where multiplying drug-resistant bacteria gradually becomes the greatest life threatening problem.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27090515     DOI: 10.2174/156720181303160520193946

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  26 in total

Review 1.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

Review 2.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

3.  Isolation, characterization, and comparative genomic analysis of vB_PlaM_Pd22F, a new bacteriophage of the family Myoviridae.

Authors:  Arif Bozdeveci; Merve Karali; Rahşan Akpinar; Şengül Alpay Karaoğlu
Journal:  Arch Virol       Date:  2022-04-02       Impact factor: 2.685

Review 4.  Topical application of bacteriophages for treatment of wound infections.

Authors:  Rachel Yoon Kyung Chang; Sandra Morales; Yuko Okamoto; Hak-Kim Chan
Journal:  Transl Res       Date:  2020-03-19       Impact factor: 7.012

Review 5.  Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases.

Authors:  Andrzej Górski; Ryszard Międzybrodzki; Beata Weber-Dąbrowska; Wojciech Fortuna; Sławomir Letkiewicz; Paweł Rogóż; Ewa Jończyk-Matysiak; Krystyna Dąbrowska; Joanna Majewska; Jan Borysowski
Journal:  Front Microbiol       Date:  2016-09-26       Impact factor: 5.640

6.  Bacteriophages in the gastrointestinal tract and their implications.

Authors:  Marzanna Łusiak-Szelachowska; Beata Weber-Dąbrowska; Ewa Jończyk-Matysiak; Renata Wojciechowska; Andrzej Górski
Journal:  Gut Pathog       Date:  2017-08-10       Impact factor: 4.181

Review 7.  Prospects of Phage Application in the Treatment of Acne Caused by Propionibacterium acnes.

Authors:  Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska; Maciej Żaczek; Ryszard Międzybrodzki; Sławomir Letkiewicz; Marzanna Łusiak-Szelchowska; Andrzej Górski
Journal:  Front Microbiol       Date:  2017-02-08       Impact factor: 5.640

8.  Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments.

Authors:  Apurva Virmani Johri; Pranav Johri; Naomi Hoyle; Levan Pipia; Lia Nadareishvili; Dea Nizharadze
Journal:  Front Pharmacol       Date:  2021-06-10       Impact factor: 5.810

9.  Phage Therapy as a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant Acinetobacter baumannii in Mice.

Authors:  Yunfen Hua; Tingting Luo; Yiqi Yang; Dong Dong; Rui Wang; Yanjun Wang; Mengsha Xu; Xiaokui Guo; Fupin Hu; Ping He
Journal:  Front Microbiol       Date:  2018-01-09       Impact factor: 5.640

10.  Selection of Potential Therapeutic Bacteriophages that Lyse a CTX-M-15 Extended Spectrum β-Lactamase Producing Salmonella enterica Serovar Typhi Strain from the Democratic Republic of the Congo.

Authors:  Elene Kakabadze; Khatuna Makalatia; Nino Grdzelishvili; Nata Bakuradze; Marina Goderdzishvili; Ia Kusradze; Marie-France Phoba; Octavie Lunguya; Cédric Lood; Rob Lavigne; Jan Jacobs; Stijn Deborggraeve; Tessa De Block; Sandra Van Puyvelde; David Lee; Aidan Coffey; Anahit Sedrakyan; Patrick Soentjens; Daniel De Vos; Jean-Paul Pirnay; Nina Chanishvili
Journal:  Viruses       Date:  2018-04-03       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.